Will be interesting to see what the company will achieve during the current financed period ! I'd say whilst not impossible, the liklihood of further placings at these levels diminishes with each round ?
Take care ..
Indeed .. that was just my rare thoughts on sp movement til oo sorted .. their aim was �8M .. they already got �7.5 from book build so I think we can safely say they will reach their initial target ?
Time will tell as ever .. take care ..
I'm guessing it will be fairly quiet share price wise until the 9th May at least .. then once the oo is all sorted, and a line drawn under it, anything could happen I suppose ?
Take care all ..
Folks like ire Mellman, Keith flaherty, Paul chapman plus many others now .. with all the massive amount of 'science' out there, I would think, wouldn't spend any time working with the chaff !!
Take care all ..
What remains, regardless of 'dilution', are the requirements for bods options to be taken .. 22p for over 30 days ..
Now that is irrespective of market cap !
Take care all ..
Indeed �20M is peanuts to Genentech .. which is why I think Scancell dont want to give away anything for nothing ! (Unless they really really really have to.. which isn't yet!) .
Take care !
Even should the the unfortunate happen and them not get one of the �20M pots ... I believe there could well be a plan B involving Ira Mellman / Genentech perhaps !?
But that's just a thought !
Take care ..
Worth remembering that the team members of the 'project blueprint' grand challenge bid are already working together with the �30K from CRUK to put the final touches to their pitch !
Some team !
Take care ...
Morning TF .. hope it goes your way today... I'd hate it if it was the 'pool that sealed your fate !
The 4th platform whilst not solely scancells but a joint venture with bioNTech perhaps .. a combination of platform technologies .
"This research collaboration combines Scancell's Moditope� immunotherapy platform and BioNTech's platform technology for high-throughput cloning and characterisation of naturally selected T cell receptors."
This is a space not previously occupied by scancell and I believe worthy of the 4th platform description ?
Take care ..
I guess scancell is still at the 'land grab' stage !
But their proof of concept through scib1 for the immunobody platform really is astonishing !
With more to come a manageable time frame away .. they seem confident to shoulder the risk to gain further reward !!
Take care ..